Synapse - Adam Schoenfeld

Results (134)

Analysis of tumor mutational burden, progression-free survival, and local-regional control in patents with locally advanced non-small cell lung cancer treated with chemoradiation and durvalumab

Journal Article

Lebow, E. S.; Shepherd, A.; Eichholz, J. E.; Offin, M.; Gelblum, D. Y.; Wu, A. J.; Simone, C. B. 2nd; Schoenfeld, A. J.; Jones, D. R.; Rimner, A.; more...
JAMA Network Open (2023)

Fulltext@MSK | Save

SRC family kinase inhibition targets YES1 and YAP1 as primary drivers of lung cancer and as mediators of acquired resistance to ALK and epidermal growth factor receptor inhibitors

Journal Article

Sato, H.; Kubota, D.; Qiao, H.; Jungbluth, A.; Rekhtman, N.; Schoenfeld, A. J.; Yu, H. A.; Riely, G. J.; Toyooka, S.; Lovly, C. M.; more...
JCO Precision Oncology (2022)

Fulltext@MSK | Save

A phase I study of personalized adoptive TCR T cell therapy in patients with solid tumors: Safety, efficacy, and T cell trafficking to tumors of non-virally gene edited T cells

Meeting Abstract

Foy, S.; Jacoby, K.; Bota, D.; Hunter, T.; Schoenfeld, A.; Pan, Z.; Stawiski, E.; Ma, Y.; Lu, W.; Peng, S. M.; more...
Journal for ImmunoTherapy of Cancer (2022)

Fulltext@MSK | Save

A reproducible pipeline for analysis of multiplex imaging (MIBI) data with application to uncovering novel features of the tumorimmune microenvironment

Meeting Abstract

Maxey, J.; Thompson, M.; Campbell, K.; Kamphaus, B.; Bustami, Z.; Santulli-Marotto, S.; Wells, D.; Boffo, S.; Salvador, L.; Scumpia, P.; more...
Journal for ImmunoTherapy of Cancer (2022)

Fulltext@MSK | Save

ITIL-306-201: A multicenter, first-in-human phase 1a/1b study of ITIL-306, an engineered autologous tumor-infiltrating lymphocyte (TIL) cell therapy product, in adults with advanced solid tumor

Meeting Abstract

Ward, J.; Ghobadi, A.; Liao, J.; Schoenfeld, A.; Tykodi, S.; Jiang, Y.; Le Gall, J.; Alvarez-Rodriguez, R.; Sherman, M.; Singson, T.; more...
Journal for ImmunoTherapy of Cancer (2022)

Fulltext@MSK | Save

ZENYTH-ESO Substudy 1 (GSK3901961), cohort 1: A first-in-human study to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with non-small cell lung cancer

Meeting Abstract

Wermke, M.; Ullrich, R.; Yachnin, J.; Mielke, S.; Patel, R.; Yushak, M. L.; Schoenfeld, A. J.; Desai, J.; Altan, M.; D'angelo, S. P.; more...
Oncology Research and Treatment (2022)

Fulltext@MSK | Save

ZENYTH-ESO: Master protocol to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma, myxoid/round cell liposarcoma and nonsmall cell lung cancer [Substudy 1 (GSK3901961) and Substudy 2 (GSK3845097)]

Meeting Abstract

Ullrich, R.; Wermke, M.; Yachnin, J.; Mielke, S.; Patel, R.; Yushak, M. L.; Schoenfeld, A. J.; Desai, J.; Altan, M.; D'Angelo, S. P.; more...
Oncology Research and Treatment (2022)

Fulltext@MSK | Save

Impact of intratumoral microbiome on immunotherapy treatment outcomes in patients with advanced non-small cell lung cancer

Meeting Abstract

Elkrief, A.; Bowman, A.; Rizvi, H.; Hellmann, M.; Riely, G. J.; Schoenfeld, A. J.; Ladanyi, M.; Vanderbilt, C. M.
Annals of Oncology (2022)

Fulltext@MSK | Save

Interim results of an ongoing phase 1/2a study of HPN328, a tri-specific, half-life extended, DLL3-targeting, T-cell engager, in patients with small cell lung cancer and other neuroendocrine cancers